Document is current

Any future updates will be listed below

Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy

Crossref DOI link: https://doi.org/10.1038/s41419-022-04743-7

Published Online: 2022-04-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark